SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim

UC Davis has been activated as a clinical trial site for CER-1236, an experimental cancer treatment, and will also serve as its primary manufacturing site. This is expected to expand patient recruitment and streamline logistics. SRX Global (SRXH) announced this milestone, which follows its agreement to acquire CERo Therapeutics (CERO). Preliminary trial results show no severe adverse events, but are not yet sufficient to establish safety or efficacy.

SRX Global (SRXH) will acquire CERo Therapeutics, a cellular immunotherapy company, to accelerate development of CER-1236 for blood cancers. The deal combines SRX's public infrastructure with CERo's oncology platform, aiming to enhance capital access and operational resources. CER-1236 is in Phase 1 trials, with preliminary data showing no dose-limiting toxicities in recent cohorts. The transaction is subject to closing conditions and regulatory approvals.

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

SRX Global Inc. (NYSE American: SRXH) said its board authorized a share repurchase plan to buy up to 10 million shares or as much as 50% of shares outstanding. The company allocated up to $20 million for repurchases through July 9, 2027, funded by cash on hand, with timing dependent on market and other factors.

SRX Global (NYSE American: SRXH) said it made a strategic investment in clinical-stage biodefense company ARMR Sciences. ARMR’s lead candidate ARMR-100, in a Phase 1/2 trial, recently reported generating an anti-fentanyl immune response in humans with favorable safety data. The company plans to start evaluating protection against fentanyl later in 2026.